There are currently 210 treatments and cures in phase III in California's pipeline and companies are expected to invest $50 billion in new facilities, equipment and employees. Capturing this unprecedented opportunity requires a conscious effort by California's leadership. At the launch of BayBio: IMPACT 2009, life sciences leaders will present a strategic action plan to capture this massive investment in the State of California.

The BayBio: IMPACT report is the preeminent, in-depth report on the state of California's life sciences industry and its productivity. No other report measures the number of treatments, cures and technologies measured in BayBio: IMPACT and no other comprehensive report identifies each company and its development pipeline.

At the launch event during JP Morgan, life sciences executives will provide a perspective on innovation and the challenges of developing new treatments and cures in California.

IMPACT Speakers
Matt Gardner
President & CEO, BayBio

Pierre Cassigneul
President & CEO, XDx Inc.

Hoyoung Huh
President & CEO, BiPar Sciences

• What: BayBio:IMPACT 2009 Launch
  
• When: 9:30am - 11:00am, Wednesday, January 14, 2009
  
• Where: Grand Hyatt at Union Square, San Francisco
  
• RSVP: 650-871-7101x207 or travis@baybio.org
  Seating is limited. Please RSVP.
  
  

ARCHIVED REPORTS

• Read the 2009 Report.
• Read the 2008 Report.
• Read the 2007 report.
• Read the 2005 report.